

## MENTAL HEALTH AND ADDICTION REFERENCES

1. Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. *Am J Drug Alcohol Abuse*. 2011;37(1):1-11.
2. Martins SS, Keyes KM, Storr CL. Pathways between non-medical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Drug Alcohol Depend*. 2009;103:16-24.
3. Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. *J Addict Med*. 2011;5(4):254-263.
4. Seal KH, Shi Y, Cohen G. Association of Mental Health Disorders With Prescription Opioids and High-Risk Opioid Use in US Veterans of Iraq and Afghanistan. *JAMA*. 2012;307:940-947.
5. Brady KT, Myrick H, Sonne S. Comorbid addiction and affective disorders. In: *In: Graham AW, Schultz TK, Eds. Principles of Addiction Medicine*. Vol Second Edition. Chevy Chase, Md: American Society of Addiction Medicine; 1998.
6. Fishman MJ, Wu LT, Woody GE. Buprenorphine for Prescription Opioid Addiction in a Patient With Depression and Alcohol Dependence. *Am J Psychiatry*. 2011;168(7):675-679.
7. Pani PP, Vacca R, Troqu E, et al. Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. *Cochrane Database Syst Rev*. 2010;8(9):CD008373.
8. Trémeau F, Darreye A, Staner L, et al. Suicidality in opioid-dependent subjects. *Am J Addict*. 2008;17(3):187-194.
9. Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. *Addiction*. 2002;97(11):1383-1394.
10. Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). 2003.
11. SAMHSA. *Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians*. 2001.
12. FDA. Medication Guide: Butrans™ CIII (buprenorphine) Transdermal System. 2010.
13. Papastavrou E, Farmakas A, Karayiannis G, et al. Co morbidity of Post-Traumatic-Stress Disorders and Substance Use Disorder. *Health Science Journal*. *Health Sci J*. 2011;5(2):107-117.
14. Verheul R. Co-morbidity of personality disorders in individuals with substance use disorders. *Eur Psychiatry*. 2001;16(5):274-282.
15. Sansone RA, Whitecar P, Wiederman MW. The prevalence of borderline personality among buprenorphine patients. *Int J Psychiatry Med*. 2008;38(2):217-226.
16. Kidorf M, Disney ER, King VL, et al. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. *Drug Alcohol Depend*. 2004;74(2):115-122.

17. Renner J, Saxon A, Levounis P. [Buprenorphine Update and Evolving Standards of Care](#). IPS: The Mental Health Services Conference. October 2015. New York City.
18. American Psychiatric Association. [Substance-Related and Addictive Disorders](#). APA. 2013.
19. Hesse M. [The ASRS-6 Has Two Latent Factors: Attention Deficit and Hyperactivity](#). *J Atten Disord*. 2011;17(3):203-207.